Premium
AN UNDETECTABLE PB MRD STATUS SHOULD BE THE THERAPEUTIC GOAL WITH VENETOCLAX THERAPY IN RELAPSED/ REFRACTORY CLL
Author(s) -
Handunnetti S.M.,
Lew T.E.,
Lin V.S.,
Anderson M.A.,
Carney D.,
Wolf M.,
Came N.,
Juneja S.,
Westerman D.,
Tam C.S.,
Roberts A.W.,
Seymour J.F.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.70_2629
Subject(s) - venetoclax , payment , medicine , ven , position (finance) , family medicine , business , leukemia , humanities , chronic lymphocytic leukemia , philosophy , finance
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom